Rick Doblin and MAPS: The 35-Year Campaign to Make Psychedelics Medicine

In 1986, Rick Doblin founded the Multidisciplinary Association for Psychedelic Studies with a goal that virtually everyone in science, medicine, and policy considered delusional: to shepherd MDMA and other psychedelic compounds through the FDA approval process. Here is the story of how a Harvard-trained policy researcher spent 35 years making the impossible happen.

Who Doblin is

Rick Doblin has a PhD in public policy from Harvard's Kennedy School. His dissertation was on the regulation of the medical uses of psychedelics. He wrote it in 1991, when no one in policy circles considered psychedelic regulation a serious field of study.

The personal experience that motivated him was a 1982 MDMA experience that he described as profoundly therapeutic — a quality of emotional openness and self-insight that seemed to him obviously clinically valuable. When MDMA was scheduled in 1985, Doblin decided that the regulatory path — however improbable — was the only path that would permanently re-establish access.

He was 23. He founded MAPS three years later.

The early years — 1986-2000

The early MAPS years were defined by a single strategic problem: no one would fund psychedelic research, and no institution would conduct it. Doblin spent these years in the margins — filing regulatory comments, pursuing legal challenges to the MDMA scheduling, and conducting the Phase 1 safety studies that were the necessary precondition for everything that followed.

The work was unglamorous, slow, and widely considered pointless. MAPS operated on a tiny budget. Doblin was not taken seriously by most of the scientific establishment. He continued anyway.

The strategic approach

Doblin's strategic insight — which distinguished him from the counterculture psychedelic advocates who had preceded him — was that the system had to be engaged, not opposed. The FDA approval process existed. It was demanding and slow. It was also the only path to permanent, protected, mainstream access.

This meant conducting trials with the methodological rigor that the FDA required. It meant engaging with regulators rather than denouncing them. It meant separating the therapeutic question (does MDMA help PTSD?) from the cultural question (should psychedelics be freely available to everyone?) and answering only the therapeutic question in clinical contexts.

The strategy required patience that most people could not sustain across decades.

The MDMA PTSD trials

MAPS chose PTSD as the primary indication for MDMA-assisted therapy for strategic and scientific reasons. PTSD represented an enormous unmet need — millions of people with inadequate treatment options. MDMA's mechanism — reducing activity in the amygdala, increasing oxytocin, allowing emotionally charged memories to be processed without overwhelming fear response — was theoretically well-suited to the condition.

The clinical trial program built slowly from Phase 1 safety studies through Phase 2 efficacy studies to the Phase 3 trials that are required for FDA approval. Each phase produced results that sustained the case for continuing.

The phase 3 results

The Phase 3 results, published across multiple papers in Nature Medicine and other high-impact journals, showed MDMA-assisted therapy producing remission from PTSD in 67-71% of participants — compared to approximately 32% in the therapy-alone arm. These are striking numbers for a condition that is notoriously treatment-resistant.

The magnitude of the effect, the consistency across trials, and the durability of the results (maintained at follow-up) constituted the strongest clinical evidence for any psychedelic-assisted therapy assembled to that point.

The FDA advisory committee

In 2024, an FDA advisory committee reviewed the Phase 3 data. The outcome was complicated — the committee raised concerns about functional unblinding (participants could often tell whether they had received MDMA or placebo) and about trial design. The FDA did not grant approval at that juncture.

The process continued. MAPS responded to the committee's concerns and continued engaging with the regulatory process. The story is not over.

Doblin has said: My goal is a world where people can be trained as psychedelic therapists, where anyone who needs this medicine can access it, and where the long-term consequences of Schedule 1 for human mental health can be reversed. After 35 years of working toward that goal, the phase 3 data is in. The treatment works. The regulatory process is the remaining obstacle.

Beyond MDMA — the broader MAPS mission

MAPS has expanded beyond MDMA. Psilocybin research, ibogaine studies, and cannabis research are all part of the current portfolio. The institutional infrastructure built for MDMA — the training programs, the regulatory relationships, the clinical network — is being applied to other compounds.

This infrastructure is itself one of Doblin's most important contributions. The capacity to conduct rigorous psychedelic research did not exist in 1986. MAPS built much of it.

What Doblin believes

Doblin's stated vision has remained consistent across 35 years: a world in which psychedelic therapy is mainstream medicine, trained therapists are widely available, and the mental health burden created by inadequate treatment of trauma, addiction, and depression is significantly reduced.

He does not frame this as a psychedelic cultural project. He frames it as a public health project. The distinction has been strategically essential — it is what allowed MAPS to do the work that counterculture advocacy could not.

The Technospermia reading

Doblin represents something specific in the larger story: the re-emergence of consciousness technology through the formal scientific and regulatory channel. The counterculture channel — Leary, the 1960s — was shut down. The scientific channel could not be shut down, only delayed.

The Technospermia framework reads MAPS as the institutional mechanism through which the technology forced its way back into legitimate human systems. Doblin's 35 years of methodical, unglamorous, regulatory work is not separate from the psychedelic story — it is the most important chapter in the re-emergence of that story.

For the MDMA therapy evidence specifically, read MDMA therapy for PTSD. For the broader context of why psychedelics were suppressed, see the war on drugs. For the renaissance that MAPS helped create, read the psychedelic renaissance. For the FDA timeline specifically, see psilocybin FDA approval timeline.